Mylan Inc. (NASDAQ:MYL)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a research note issued on Tuesday. They presently have a $55.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 52.52% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research lowered Mylan from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Leerink Swann upped their target price on Mylan from $51.00 to $55.00 and gave the stock an “outperform” rating in a research note on Monday, August 15th. TheStreet raised Mylan from a “hold” rating to a “buy” rating in a research note on Friday, August 12th. Bank of America Corp. reaffirmed a “buy” rating and issued a $70.00 target price on shares of Mylan in a research note on Wednesday, August 24th. Finally, Wells Fargo & Co. reaffirmed a “market perform” rating and issued a $44.00 target price on shares of Mylan in a research note on Thursday, August 25th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Mylan presently has an average rating of “Buy” and a consensus target price of $52.83.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) traded down 1.85% during mid-day trading on Tuesday, reaching $36.06. 3,698,152 shares of the company’s stock traded hands. Mylan has a 12 month low of $33.60 and a 12 month high of $55.51. The company has a 50 day moving average price of $37.27 and a 200-day moving average price of $42.19. The stock has a market cap of $19.30 billion, a P/E ratio of 72.26 and a beta of 1.10.

Mylan (NASDAQ:MYL) last released its earnings results on Wednesday, November 9th. The company reported $1.38 EPS for the quarter, missing the Zacks’ consensus estimate of $1.45 by $0.07. The business had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.12 billion. Mylan had a return on equity of 22.04% and a net margin of 2.50%. The company’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.43 earnings per share. On average, analysts anticipate that Mylan will post $4.76 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Mylan’s (MYL) “Buy” Rating Reiterated at BTIG Research” was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/29/mylans-myl-buy-rating-reiterated-at-btig-research.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Nuveen Asset Management LLC boosted its position in shares of Mylan by 22.5% in the first quarter. Nuveen Asset Management LLC now owns 36,195 shares of the company’s stock worth $1,678,000 after buying an additional 6,636 shares during the period. LPL Financial LLC boosted its position in shares of Mylan by 21.8% in the first quarter. LPL Financial LLC now owns 45,698 shares of the company’s stock worth $2,098,000 after buying an additional 8,170 shares during the period. Arizona State Retirement System boosted its position in shares of Mylan by 2.3% in the first quarter. Arizona State Retirement System now owns 111,808 shares of the company’s stock worth $5,182,000 after buying an additional 2,500 shares during the period. Integrated Investment Consultants LLC bought a new position in shares of Mylan during the second quarter worth approximately $145,000. Finally, Park National Corp OH boosted its position in shares of Mylan by 0.5% in the second quarter. Park National Corp OH now owns 5,875 shares of the company’s stock worth $254,000 after buying an additional 27 shares during the period. Institutional investors and hedge funds own 60.29% of the company’s stock.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

5 Day Chart for NASDAQ:MYL

Receive News & Stock Ratings for Mylan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan Inc. and related stocks with our FREE daily email newsletter.